Dermira Inc (DERM) Insider Eugene A. Bauer Sells 3,000 Shares

Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $27.07, for a total transaction of $81,210.00. Following the sale, the insider now owns 5,802 shares of the company’s stock, valued at approximately $157,060.14. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Eugene A. Bauer also recently made the following trade(s):

  • On Monday, December 18th, Eugene A. Bauer sold 3,000 shares of Dermira stock. The stock was sold at an average price of $27.34, for a total transaction of $82,020.00.

Dermira Inc (DERM) traded down $0.63 during mid-day trading on Friday, reaching $28.08. 992,000 shares of the company traded hands, compared to its average volume of 759,267. Dermira Inc has a 1 year low of $21.35 and a 1 year high of $38.75. The stock has a market cap of $1,140.00, a P/E ratio of -4.51 and a beta of 0.80. The company has a debt-to-equity ratio of 1.40, a quick ratio of 4.68 and a current ratio of 4.68.

DERM has been the subject of several recent analyst reports. Cantor Fitzgerald set a $45.00 price objective on shares of Dermira and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 price target (down previously from $46.00) on shares of Dermira in a research report on Tuesday, November 7th. Mizuho reiterated a “buy” rating and issued a $43.00 price target (up previously from $40.00) on shares of Dermira in a research report on Thursday, September 7th. BidaskClub upgraded shares of Dermira from a “hold” rating to a “buy” rating in a research report on Wednesday, December 20th. Finally, Guggenheim reiterated a “buy” rating and issued a $30.00 price target on shares of Dermira in a research report on Thursday, December 14th. Three investment analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $41.00.

Institutional investors and hedge funds have recently made changes to their positions in the business. Platinum Investment Management Ltd. increased its stake in Dermira by 28.8% in the 2nd quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock valued at $1,681,000 after buying an additional 12,900 shares during the period. Jennison Associates LLC increased its stake in Dermira by 0.3% in the 3rd quarter. Jennison Associates LLC now owns 2,640,740 shares of the biopharmaceutical company’s stock valued at $71,300,000 after buying an additional 7,746 shares during the period. Schwab Charles Investment Management Inc. increased its stake in Dermira by 24.1% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 140,495 shares of the biopharmaceutical company’s stock valued at $4,095,000 after buying an additional 27,259 shares during the period. Vanguard Group Inc. increased its stake in Dermira by 9.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,397,857 shares of the biopharmaceutical company’s stock valued at $40,735,000 after buying an additional 125,157 shares during the period. Finally, Ardsley Advisory Partners acquired a new position in Dermira in the 2nd quarter valued at $291,000. 99.47% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.chaffeybreeze.com/2018/01/05/dermira-inc-derm-insider-eugene-a-bauer-sells-3000-shares.html.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply